共 50 条
- [21] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
- [27] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors Cancer Chemotherapy and Pharmacology, 2024, 93 : 177 - 189
- [30] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond Current Oncology Reports, 2011, 13 : 442 - 449